natgillin/translations-raw huggingface dataset:
Redness Swelling Fever (>38°C) Fever (>39°C) - per-dose frequency - per-subject frequency Drowsiness
Polni odmerek induracija bolečina pordelost oteklost zvišana telesna temperatura (> 38 °C) zvišana telesna temperatura (> 39 °C) - pogostnost na odmerek - pogostnost na preiskovanca zaspanost
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, acute and repeated dose toxicity, local tolerance, female fertility, embryo-fetal and postnatal toxicity (up to the end of the lactation period).
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, akutne toksičnosti in toksičnosti pri ponavljajočih se odmerkih, lokalne tolerance, plodnosti pri samicah, embrio-fetalne in postnatalne toksičnosti (do konca obdobja laktacije) ne kažejo posebnega tveganja za človeka.
The side effects listed below have happened in the days or weeks after vaccination with other vaccines given routinely every year to prevent flu.
Neželeni učinki, ki so navedeni spodaj, so se pojavili v dnevih ali tednih po cepljenju z drugimi cepivi,
PHARMACEUTICAL FORM AND CONTENTS Adjuvant emulsion for injection 25 vials: emulsion
FARMACEVTSKA OBLIKA IN VSEBINA Emulzija adjuvansa za injiciranje 25 vial: emulzija
1 Geometric Mean Titre
1Geometrična sredina titrov
Doses of 15, 5, 1.7 or 0.6 micrograms of HA were tested in the homologous challenge experiment, and doses of 15, 7.5, 3.8 or 1.75 micrograms of HA were tested in the heterologous challenge experiment.
V homolognem provokacijskem poskusu so raziskovali odmerke 15, 5, 1,7 ali 0,6 mikrograma HA, v heterolognem provokacijskem poskusu pa odmerke 15, 7,5 3,8 ali 1,75 mikrograma HA.
Excipient with known effect The vaccines contains 5 micrograms thiomersal (see section 4.4).
Cepivo vsebuje 5 mikrogramov tiomersala (glejte poglavje 4.4).
Like all medicines, this vaccine can cause side effects, although not everybody gets them.
Možni neželeni učinki Kot vsa cepiva ima lahko tudi to cepivo neželene učinke, ki pa se ne pojavijo pri vseh cepljenih osebah.
It is intended to be given before or during the next influenza (flu) pandemic to prevent flu caused by the H5N1 type of the virus.
Namenjeno je za preprečevanje gripe, ki jo povzroča tip virusa H5N1, pred ali med naslednjo pandemijo gripe.
After two doses given 21 days or 6 months apart, 96.0% of subjects had a 4-fold increase in serum neutralising antibody titre and 98-100% had a titre of at least 1:80.
Po dveh odmerkih apliciranih 21 dni ali 6 mesecev narazen je 96,0 % preiskovancev imelo 4-krat večji titer nevtralizacijskih protiteles v serumu in 98-100 % preiskovancev je imelo titer vsaj 1:80.
Active immunisation against H5N1 subtype of Influenza A virus.
Aktivna imunizacija proti podtipu H5N1 virusa influence A.
Prepandrix should under no circumstances be administered intravascularly.
Cepiva Prepandrix se v nobenem primeru ne sme injicirati v žilo.
However, in the event of an officially declared influenza pandemic, persons previously vaccinated with one or two doses of Prepandrix that contained HA antigen derived from a different clade of the same influenza subtype as the pandemic influenza strain may receive a single dose of Adjupanrix instead of two doses that are required in previously unvaccinated individuals.
Celotno cepljenje s cepivom Prepandrix obsega dva odmerka.V primeru uradno razglašene pandemije gripe pa lahko dobijo osebe, predhodno cepljene z enim ali dvema odmerkoma cepiva Prepandrix, ki je vsebovalo HA-antigen iz druge gruče (clade) istega podtipa gripe, kot je pandemski sev, en sam odmerek cepiva Adjupanrix namesto dveh odmerkov, ki sta potrebna za predhodno necepljene osebe.
At day 42, the anti-HA antibody responses were as follows:
Na 42. dan so bili odzivi anti-HA protiteles naslednji:
There are no data on co-administration of Prepandrix with other vaccines.
Podatkov o sočasni uporabi cepiva Prepandrix z drugimi cepivi ni.
In each experiment, four groups of six ferrets were immunized intramuscularly with an AS03 adjuvanted vaccine containing HA derived from H5N1/A/Vietnam/1194/04 (NIBRG-14).
V vsakem poskusu so štiri skupine s šestimi živalmi intramuskularno cepili s cepivom, ki je imelo kot adjuvans AS03 in je vsebovalo HA, pridobljen iz H5N1/A/Vietnam/1194/04 (NIBRG-14).
These side effects may also happen with Prepandrix.
Ti neželeni učinki se lahko pojavijo tudi pri cepivu Prepandrix.
What Prepandrix looks like and contents of the pack
Izgled cepiva Prepandrix in vsebina pakiranja
Immune response to A/Vietnam/1194/2004 (D42) 61 to 70 years
Imunski odziv proti A/Vietnam/1194/2004 (D42) 61 do 70 let
NAME OF THE MEDICINAL PRODUCT Emulsion for emulsion for injection for Prepandrix
IME ZDRAVILA Emulzija za emulzijo za injiciranje za Prepandrix
Prepandrix contains thiomersal
Cepivo Prepandrix vsebuje tiomersal
- If you get any side effects, talk to your doctor.
- Če opazite katerikoli neželeni učinek, se posvetujte s svojim zdravnikom.
Very limited data in seronegative subjects >80 years of age (N=5) showed that no subject achieved seroprotection following two administrations of a single dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1).
Zelo omejeni podatki pri seronegativnih preiskovancih, starejših od 80 let (n = 5), so pokazali, da noben preiskovanec ni dosegel serološke zaščite po dvakratni uporabi enega odmerka cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Vietnam/1194/2004 (H5N1).
In clinical trials in which subjects (N=201) received Prepandrix containing 3.75 microgram HA/AS03 of A/Indonesia/05/2005 (H5N1) strain, the types and frequencies of adverse reactions were comparable with those reported below.
V kliničnem preskušanju, v katerem so preiskovanci (n = 201) dobili cepivo Prepandrix, ki je vsebovalo 3,75 mikrograma HA/AS03 seva A/Indonesia/05/2005 (H5N1), so bile vrste in pogostnosti neželenih učinkov primerljive tistim, ki so navedene spodaj.
Blood and lymphatic system disorders Common: lymphadenopathy
Bolezni krvi in limfatičnega sistema
Therefore monitoring of temperature and measures to lower the temperature (such as giving paracetamol or other medicines that lower fever) after each dose are recommended.
Zato je otroku po vsakem odmerku cepiva priporočljivo spremljati telesno temperaturo in uporabiti ukrepe za njeno znižanje (npr. otroku dati paracetamol ali drugo zdravilo za znižanje zvišane telesne temperature).
List of adverse reactions Adverse reactions reported are listed according to the following frequency:
Opisani neželeni učinki so navedeni po naslednjih skupinah pogostnosti: Pogostnosti so navedene kot:
2 % of subjects with titres ≥1:28
1geometrična sredina titrov 2% preiskovancev s titri ≥1:28
If you get any side effects, talk to your doctor.
Če opazite katerikoli neželeni učinek, se posvetujte s svojim zdravnikom.
The seroprotection at month 6, 12 and 24 were as follows:
Deleži serološke zaščite 6., 12. in 24. mesec so bili:
21 days after 2nd dose N=48
21 dni po drugem odmerku n=48
Seroprotection rate
Delež serološke zaščite proti
In addition, 44.8% and 56.1% of subjects in respective dose groups had a 4-fold increase in serum neutralising antibody titres from day 0 to day 42 and 96.6% and 100% of subjects had a titre of at least 1:80 at day 42.
Poleg tega je imelo v posameznih odmernih skupinah 4-kraten porast titrov nevtralizirajočih protiteles v serumu od dneva 0 do 42. dneva 44,8 % in 56,1 % preiskovancev in titer vsaj 1:80 96,6 % in 100 % preiskovancev
Suspension: multidose vial containing the antigen, Emulsion: multidose vial containing the adjuvant.
Cepivo Prepandrix je na voljo v dveh vsebnikih: suspenzija: večodmerna viala z antigenom, emulzija: večodmerna viala z adjuvansom.
Your doctor or nurse will give you Prepandrix.
S cepivom Prepandrix vas bo cepil zdravnik ali medicinska sestra.
21 days after 1st dose N=55
21 dni po prvem odmerku n=55
In a clinical study, children 3 to 9 years of age have received either two adult (0.5 ml) or two half adult (0.25 ml) doses of a similar vaccine containing A/Vietnam/1194/2004.
V klinični študiji so otroci, stari od 3 do 9 let, prejeli dvakrat bodisi odmerek za odrasle (0,5 ml) bodisi polovični odmerek za odrasle (0,25 ml) podobnega cepiva, ki je vsebovalo sev A/Vietnam/1194/2004.
• if you have previously had a sudden life-threatening allergic reaction to any ingredient of this vaccine (listed in section 6) or to anything else that may be present in very small amounts such as: egg and chicken protein, ovalbumin, formaldehyde, gentamicin sulphate (antibiotic) or sodium deoxycholate.
• če ste kdaj imeli nenadno, življenjsko ogrožajočo alergijsko reakcijo na katerokoli sestavino tega cepiva (navedeno v poglavju 6) ali na karkoli, kar je lahko prisotno v zelo majhnih količinah, kot so: jajčne in piščančje beljakovine, ovalbumin, formaldehid, gentamicinijev sulfat (antibiotik) ali natrijev deoksiholat.
How to store Prepandrix
Kako uporabljati cepivo Prepandrix
Clinical studies have evaluated the incidence of adverse reactions in approximately 5,000 subjects 18 years old and above who received Prepandrix containing A/Vietnam/1194/2004 (H5N1) strain with at least 3.75 µg HA.
S kliničnimi študijami so ocenili pojavnost neželenih učinkov pri približno 5.000 preiskovancih, starih 18 let in več cepljenih s cepivom Prepandrix, ki je vsebovalo sev A/Vietnam/1194/2004 (H5N1) z vsaj 3,75 µg HA.
2.5 ml After mixing with adjuvant emulsion: 10 doses of 0.5 ml)
2,5 ml Po premešanju z emulzijo adjuvansa: 10 odmerkov po 0,5 ml.
Month 6 N=48
6. mesec n=48
The seroprotection rates 6, 12, 24 and 36 months after the first dose were as follows: anti-HA antibody
Deleži serološke zaščite 6, 12 in 24 mesecev po cepljenju so bili: anti-HA protitelesa
Month N=35
12. mesec n=35
Regardless of whether one or two doses of priming vaccine had been given 6 months earlier, the seroprotection rates against A/Indonesia were >80% after a dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 and the seroprotection rates against A/Vietnam were >90% after a dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005.
Ne glede na to, ali sta bili 6 mesecev prej uporabljena eden ali dva odmerka primarnega cepiva so bili deleži serološke zaščite proti A/Indonesia po odmerku cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Vietnam/1194/2004 > 80 %, deleži serološke zaščite proti A/Vietnam po odmerku cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Indonesia/05/2005 pa > 90 %.
Contents of the pack and other information
Shranjevanje cepiva Prepandrix Vsebina pakiranja in dodatne informacije
Immune response against A/Indonesia/05/2005 (H5N1) In a clinical study (Q-Pan-H5N1-001) in which two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005 were administered on days 0 and 21 to 140 subjects aged 18-60 years, the anti-HA antibody responses were as follows: anti-HA antibody
Imunski odziv proti A/Indonesia/05/2005 (H5N1) V klinični študiji (Q-Pan-H5N1-001), v kateri je 140 preiskovancev, starih od 18 do 60 let, dobilo na dan 0 in 21 dva odmerka cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Indonesia/05/2005, je bil odziv anti-HA protiteles naslednji: anti-HA protitelesa
How Prepandrix works
Kako deluje cepivo Prepandrix
The vaccine should be administered in accordance with the recommended posology (see section 3 “How Prepandrix is given”).
Po mešanju je količina cepiva Prepandrix v viali vsaj 5 ml.. Cepivo je treba uporabiti v skladu s priporočenim odmerjanjem (glejte poglavje 3 "Kako uporabljati cepivo Prepandrix").
Caution is needed when administering this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients listed in section 6.1, to thiomersal and to residues (egg and chicken protein, ovalbumin, formaldehyde, gentamicin sulphate and sodium deoxycholate).
Previdnost je potrebna pri cepljenju oseb z znano preobčutljivostjo (poleg anafilaktične reakcije) za zdravilno učinkovino, ali katerokoli pomožno snov navedeno v poglavju 6.1, tiomersal ali zaostanke (jajčne ali piščančje proteine, ovalbumin, formaldehid, gentamicinijev sulfat ali natrijev deoksiholat).
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Adjuvant emulsion for Prepandrix
IME ZDRAVILA IN POT(I) UPORABE Emulzija adjuvansa za Prepandrix i.m.
In the subjects aged 3 to 5 and 6 to 9 years old who received two doses of either a full or a half dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1), the anti-HA antibody responses against A/Indonesia/5/2005 at day 42 were as follows:
Pri preiskovancih, starih od 3 do 5 in od 6 do 9 let, ki so dvakrat dobili bodisi polni bodisi polovični odmerek cepiva z adjuvansom AS03, z vsebnostjo 3,75 µg HA, pridobljenega iz A/Vietnam/1194/2004 (H5N1), so bili odzivi anti-HA protiteles proti A/Indonesia/5/2005 na 42. dan naslednji:
After two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005 administered on days 0 and 21 to 140 subjects aged 18-60 years, the anti-HA antibody responses to A/Vietnam/1194/2004 were as follows:
Po dveh odmerkih cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Indonesia/05/2005, uporabljenih na dan 0 in 21 pri 140 preiskovancih, starih od 18 do 60 let, je bil odziv anti-HA protiteles proti A/Vietnam/1194/2004 naslednji:
• Allergic reactions leading to a dangerously low blood pressure.
• alergijske reakcije, ki nevarno znižajo krvni tlak; Če ta ni zdravljen, lahko povzroči šok.
3seroconversion factor: ratio of the post-vaccination geometric mean titre (GMT) and the prevaccination GMT.
3Faktor serokonverzije: razmerje geometrične sredine titra (GMT) po cepljenju in GMT pred cepljenjem.
4.8 Undesirable effects
Seznam neželenih učinkov
General disorders and administration site conditions Very common: induration, swelling, pain and redness at the injection site, fever, fatigue, Common: shivering, influenza like illness, injection site reactions (such as warmth, pruritus) Uncommon: malaise
Splošne težave in spremembe na mestu aplikacije Zelo pogosti: induracija, oteklina, bolečina in rdečina na mestu injiciranja, zvišana telesna temperatura, utrujenost
Prepandrix contains sodium and potassium
Cepivo Prepandrix vsebuje natrij in kalij
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELAVALEC
Month 6 N=40
6. mesec n=40
Before mixing the two components, the emulsion (adjuvant) and suspension (antigen) should be allowed to reach room temperature (for a minimum of 15 minutes); each vial should be shaken and inspected visually for any foreign particulate matter and/or abnormal physical appearance.
Preden obe komponenti zmešate skupaj, morate emulzijo (adjuvans) in suspenzijo (antigen) vsaj 15 minut pustiti, da dosežeta sobno temperaturo.
The anti-HA and neutralising antibody responses to A/Indonesia/05/2005 elicited by AS03-adjuvanted vaccine containing 3.75 µg HA derived from this same strain have been shown to be comparable with the immune responses to A/Vietnam/1194/2004 elicited by AS03-adjuvanted vaccine containing 3.75 µg HA derived from this same strain.
Odziv anti-HA in odziv nevtralizirajočih protiteles proti A/Indonesia/05/2005, ki ju povzroči cepivo z adjuvansom AS03 in vsebnostjo 3,75 µg HA pridobljeno iz istega seva, sta primerljiva imunskemu odzivu na A/Vietnam/1194/2004, ki ga povzroči cepivo z adjuvansom AS03 z vsebnostjo 3,75 µg HA
There are very limited safety and immunogenicity data available on the administration of an AS03adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) and on administration of half a dose of the vaccine (i.e. 1.875 µg HA and half the amount of AS03 adjuvant) at 0 and 21 days in children aged 3 to 9 years.
Pri otrocih, starih od 3 do 9 let, je zelo malo podatkov o varnosti in imunogenosti cepiva z adjuvansom AS03, z vsebnostjo 3,75 µg HA, pridobljenega iz A/Vietnam/1194/2004 (H5N1) in polovičnega odmerka istega cepiva (tj. 1,875 µg HA in pol količine adjuvansa AS03), uporabljenih na dan 0 in 21.
One dose of 0.5 ml at an elected date.
Odrasli, starejši od 18 let: En odmerek 0,5 ml na izbrani dan.
Cross-reactive immune response elicited by AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005 (H5N1)
Navzkrižni imunski odziv na cepivo z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Indonesia/05/2005 (H5N1)
Twenty-one days after the second dose, the seroprotection rate and the vaccine response rate against A/Vietnam/1194/2004 in subjects who received the vaccine 6 months apart were 89.6% and 95.7%, respectively.
Enaindvajset dni po drugem odmerku je bil pri preiskovancih, ki so dobili cepivo v presledku 6 mesecev, delež serološke zaščite proti A/Vietnam/1194/2004 89,6 % in delež odziva na cepivo 95,7 %.
3 % of subjects reaching a serum neutralising antibody titre of at least 1:80
3% preiskovancev, ki so dosegli titer nevtralizirajočih protiteles v serumu vsaj 1:80 Drugačna shema cepljenja
Rare: may affect up to 1 in 1,000 people
Redki: pojavijo se lahko pri največ 1 od 1.000 oseb
No post-marketing surveillance data are available following Prepandrix administration.
Podatki o spremljanju cepiva Prepandrix po pridobitvi dovoljenja za promet niso na voljo.
Administration of an AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1)
Uporaba cepiva z adjuvansom AS03, z vsebnostjo 3,75 µg HA, pridobljenega iz A/Vietnam/1194/2004 (H5N1)
Very common: headache Uncommon: paraesthesia, somnolence, dizziness
Občasni: parestezije, somnolenca, omotica
Very rare: may affect up to 1 in 10,000 people
Zelo redki:pojavijo se lahko pri največ 1 od 10.000 oseb
One dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005 administered after one or two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004.
En odmerek cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Indonesia/05/2005, uporabljen po enem ali dveh odmerkih cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Vietnam/1194/2004.
Therefore, the data that have been generated with AS03adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 are considered to be relevant to the use of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005.
Zato so podatki za cepivo z adjuvansom AS03 in vsebnostjo 3,75 µg HA pridobljeno iz A/Vietnam/1194/2004 relevantni tudi za uporabo cepiva z adjuvansom AS03 in vsebnostjo 3,75 µg HA pridobljeno iz A/Indonesia/05/2005.
• Sleepiness
• zaspanost,
• Generally feeling unwell
Občasni: splošno slabo počutje
Prepandrix should not be given:
S cepivom Prepandrix ne smete biti cepljeni:
A clinical study (D-H5N1-009) evaluated the reactogenicity in children 3 to 5 and 6 to 9 years of age who received either two adult (i.e. 0.5 ml) doses or two half adult (i.e. 0.25 ml) doses (21 days apart) of pandemic preparedness vaccine (H5N1 A/Vietnam/1194/2004 manufactured in Dresden, Germany).
S klinično študijo (D-H5N1-009) so ocenili reaktogenost pri otrocih, starih od 3 do 5 in od 6 do 9 let, ki so dobili v presledku 21 dni bodisi dva odmerka za odrasle (tj. 0,5 ml) bodisi dva polovična odmerka za odrasle (tj. 0,25 ml) cepiva za pripravljenost na pandemijo (H5N1 A/Vietnam/1194/2004,
• Warmth, itching or bruising where the injection was given
• občutek toplote, srbenje ali modrica na mestu injiciranja,
In a second study, 49 subjects aged 18-60 years received two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005 on days 0 and 21.
V drugi študiji je 49 preiskovancev, starih od 18 do 60 let, na dan 0 in 21 dobilo dva odmerka cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Indonesia/05/2005.
Gastrointestinal disorders Uncommon: gastro-intestinal symptoms (such as diarrhoea, vomiting, abdominal pain, nausea)
Občasni: prebavni simptomi (kot so driska, bruhanje, bolečine v trebuhu, navzea)
Although an adequate immune response was achieved at day 42 following two administrations of a single dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1), a higher response was observed following two administrations of a double dose of vaccine.
Po dvakratni uporabi enega odmerka cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Vietnam/1194/2004 (H5N1) je bil 42. dan sicer dosežen ustrezen imunski odziv, vendar so po dvakratni uporabi dvojnega odmerka cepiva opazili večji odziv.
Excipients:
Otroci:
In clinical studies that evaluated the immunogenicity of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) in subjects 18-60 years old, the anti-haemagglutinin (anti-HA) antibody responses were as follows:
V kliničnih študijah, ki so pri preiskovancih v starosti od 18 do 60 let ocenile imunogenost cepiva z adjuvansom AS03 in vsebnostjo 3,75 µg HA pridobljeno iz A/Vietnam/1194/2004 (H5N1), so bili odzivi protiteles na anti-hemaglutinin (anti-HA) naslednji:
Twenty-one days after the second dose, the seroprotection rate and the vaccine response rate in subjects who received the vaccine 6 months apart were 83.3% and 100%, respectively.
Enaindvajset dni po drugem odmerku je bil pri preiskovancih, ki so dobili cepivo v presledku 6 mesecev, delež serološke zaščite 83,3 % in delež odziva na cepivo 100 %.
• if you have had any allergic reaction other than a sudden life threatening allergic reaction to any ingredient contained in this vaccine (listed in section 6) or to thiomersal, to egg and chicken protein, ovalbumin formaldehyde, gentamicin sulphate (antibiotic) or to sodium deoxycholate.
• če se je pri vas kdaj pojavila kakršnakoli alergijska reakcija (poleg nenadne, življenjsko ogrožajoče alergijske reakcije) na katerokoli sestavino tega cepiva (navedeno v poglavju 6), ali na tiomersal, jajčne in piščančje beljakovine, ovalbumin, formaldehid, gentamicinijev sulfat (antibiotik) ali natrijev deoksiholat.
In another clinical study (D-Pan-H5N1-010), 297 subjects aged > 60 years (stratified in ranges from 61 to 70, 71 to 80 and > 80 years of age) received either a single or a double dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) at 0 and 21 days.
V drugi klinični študiji (D-Pan-H5N1-010) je 297 preiskovancev, starejših od 60 let (razdeljenih v skupine od 61 do 70, 71 do 80 ter > 80 let), dobilo ali en ali dva odmerka cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Vietnam/1194/2004 (H5N1) na dan 0 in 21.
Sodium chloride (NaCl) Disodium hydrogen phosphate (Na2HPO4) Potassium dihydrogen phosphate (KH2PO4) Potassium chloride (KCl) Water for injections
Viala z emulzijo: natrijev klorid (NaCl) natrijev hidrogenfosfat (Na2HPO4) kalijev dihidrogenfosfat (KH2PO4) kalijev klorid (KCl) voda za injekcije
Prepandrix suspension and emulsion for emulsion for injection Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
Prepandrix suspenzija in emulzija za emulzijo za injiciranje prepandemsko cepivo proti gripi (H5N1) z delci virionov, inaktivirano (z adjuvansom)
Skin and subcutaneous tissue disorders Common: ecchymosis at the injection site, sweating increased Uncommon: pruritus, rash
Pogosti: ekhimoza na mestu injiciranja, močnejše znojenje Občasni: srbenje, izpuščaj
“Possible side effects” may affect your ability to drive or use tools or machines.
Vpliv na sposobnost upravljanja vozil in strojev Nekateri neželeni učinki, našteti v poglavju 4, "Možni neželeni učinki", lahko vplivajo na vašo sposobnost vožnje in upravljanja z orodji in s stroji.
Month N=38
24. mesec n=38
Twenty-one days after the second dose, the seroprotection rate and the vaccine response rate in subjects who received the vaccine 12 months apart were 84.0% and 100%, respectively.
Enaindvajset dni po drugem odmerku je bil pri preiskovancih, ki so dobili cepivo v presledku 12 mesecev, delež serološke zaščite 84,0 % in delež odziva na cepivo 100 %.